Time to Sputum Culture Conversion, identifying independent - - PowerPoint PPT Presentation

time to sputum culture conversion identifying independent
SMART_READER_LITE
LIVE PREVIEW

Time to Sputum Culture Conversion, identifying independent - - PowerPoint PPT Presentation

SOA07-1073-25 Time to Sputum Culture Conversion, identifying independent modifiable risk factors Nikhil Gupte, PhD Union 2018 Background and Rationale Time to sputum culture conversion is widely used surrogate marker in early phase


slide-1
SLIDE 1

Time to Sputum Culture Conversion, identifying independent modifiable risk factors

Nikhil Gupte, PhD Union 2018

SOA07-1073-25

slide-2
SLIDE 2

Background and Rationale

  • Time to sputum culture conversion is widely used surrogate marker in early phase clinical

trials

  • Delayed sputum culture conversion may be associated with poor TB treatment outcome
  • Time to sputum culture conversion, associated risk factors among drug sensitive

pulmonary tuberculosis (PTB) have not been adequately documented

  • Clinical, socio-demographic and phyco-social characteristics that may influence time to

sputum culture conversion may be helpful

  • Characterizing factors associated with delayed time to sputum culture may help targeting

risk groups to optimize favourable TB treatment outcome.

slide-3
SLIDE 3

Methods

  • 330 Adults (≥ 18 years), drug sensitive PTB patients from Pune and Chennai – CTRIUMPh Study sites
  • Sputum culture on Lowenstein-Jensen medium was done at entry, and weeks: 2, 4, 8, 16, 24 and 72.
  • Socio-demographic, behavioural and clinical data was collected at baseline and follow-up visits using

structured case report forms

  • Time (in days) to first negative sputum culture, from AKT start date, was calculated
  • Kaplan-Meier product limit estimator was used to estimate the time to sputum culture conversion
  • Cox Proportional hazards models were used to identify independent and overlapping risk factors
slide-4
SLIDE 4

Selected baseline characteristics & K-M Curve

Baseline Characteristics

N n = 330 Age Group < 25 25 – 40 40 – 50 > 50 71 (22%) 109 (33%) 80 (24%) 70 (21%) Gender Male Female 222 (67%) 108 (33%) BMI Normal Underweight Overweight 109 (34%) 198 (61%) 18 (6%) Residence Rural Urban 176 (53%) 154 (47%) Smoking Never Current Former 189 (62%) 47 (15%) 71 (23%) Smokeless tobacco No Yes 85 (26%) 238 (74%) Baseline Characteristics N n = 330 AUDIT < 8 > 8 209 (63%) 121 (37%) DM No DM Pre DM DM 108 (37%) 73 (25%) 110 (38%) Smear Baseline Negative Positive 87 (27%) 240 (73%) Cavitation No Yes 144 (52%) 133 (48%) HIV Uninfected Infected 319 (97%) 11 (3%) TB Treatment Daily Thrice Weekly 1 (0.3) 328 (99.7%) 0.00 0.25 0.50 0.75 1.00 Proportion Culture Positive 330 135 33 24 Number at risk 50 100 150 200 Follow-up time (Days)

Time to LJ Sputum Culture Negative

Time to culture conversion Median (IQR): 35 (32 – 43)

slide-5
SLIDE 5

Exploratory & Univariable Analysis

Baseline Characteristics Medianꝉ (IQR) log-rank p- value uHR (95% CI) p-value Age Group < 25 25 – 40 40 – 50 > 50 29 (16 – 57) 33 (24 – 63) 36 (29 – 65) 58 (30 – 64) 0.004 Ref 0.68 (0.50 – 0.93) 0.62 (0.44 – 0.87) 0.57 (0.40 – 0.80) 0.02 0.01 0.001 Gender Male Female 39 (29 – 64) 31 (16 – 62) 0.002 Ref 1.44 (1.13 – 1.83)

  • 0.003

BMI Normal Underweight Overweight 34 (21 – 64) 37 (27 – 64) 31 (17 – 60) 0.05 Ref 0.88 (0.69 – 1.13) 1.56 (0.94 – 2.59)

  • 0.32

0.08 Residence Rural Urban 61 (32 – 65) 27 (15 – 51) < 0.001 Ref 1.85 (1.47 – 2.33)

  • < 0.001

Anaemia No Yes 32 (21 – 60) 42 (27 – 64) 0.001 Ref 0.66 (0.51 – 0.85)

  • 0.002

Baseline Characteristics Medianꝉ (IQR) log-rank p- value uHR (95% CI) p-value Smoking Never Current Former 32 (16 – 62) 55 (31 – 64) 62 (68 – 31) < 0.001 Ref 0.63 (0.45 – 0.89) 0.58 (0.43 – 0.77) Ref 0.01 < 0.001 Smokeless tobacco No Yes 31 (16 – 59) 46 (29 – 64) 0.04 Ref 1.30 (1.00 – 1.68)

  • 0.05

AUDIT < 8 > 8 21 (17 – 62) 58 (31 – 71) < 0.001 Ref 0.57 (0.45 – 0.73)

  • < 0.001

DM No DM Pre DM DM 31 (17 – 58) 35 (16 – 64) 39 (29 – 64) 0.04 Ref 0.73 (0.53 – 1.01) 0.72 (0.55 – 0.96)

  • 0.06

0.02 Smear Baseline Negative Positive 29 (16 – 39) 55 (29 – 64) < 0.001 Ref 0.53 (0.41 – 0.68)

  • < 0.001

Cavitation No Yes 32 (21 – 62) 51 (30 – 64) 0.03 Ref 0.77 (0.60 – 0.98)

  • 0.04

Findings: Older age, Males, Rural residence, Anaemia, Smoker, Alcohol dependence, Diabetes, AFB Positive & Cavitation were at an increased risk of delayed sputum culture conversion

slide-6
SLIDE 6

Al Alcoho hol us use di disorde der, ana naemia & smear r po positi tivity ty are in indep epen enden ently ly as assoc

  • cia

iated ed wit ith hig igh ris isk of

  • f dela

elayed ed cult lture e co conversion

slide-7
SLIDE 7

Rural residence, smear positive and high AUDIT score are affected most!

N F RHR Urban

Audit > 8

62 53 .58

Positive

Audit

< 8

69 65 .92

Rural

Smear

Negative

32 31 1.27

11-17

14 9 .48

Anemia

BMI

17-26

11 10 1.72

Smoker

Anemia

No Anemia

13 12 2.22

Urban

Smoking

Non-Smoker

90 87 1.71

slide-8
SLIDE 8

Differences in overlapping factors by gender

Rural, alcoholic males at increased risk Anaemia in rural females increases risk

N F RHR Urban

7-10

21 19 .52

Rural

HB

10-14

30 29 .97

7-11

14 14 .96

26-65

HB

11-14

11 11 2.87

Urban

age

18-25

20 20 2.58 N F RHR Urban

8-10

15 11 .36

Audit > 8

HB

10-18

39 35 .74

Positive

Audit

3-12

14 13 .80

< 8

HB

12-15

12 12 1.62

Rural

Smear

Negative

23 22 1.50

Urban

83 74 1.46

slide-9
SLIDE 9

Smoking & Alcohol dependence among males is independently associated with time to sputum culture conversion

Males Females

slide-10
SLIDE 10

Conclusions

  • Smoking and alcohol consumption increased the risk of longer time to

sputum culture conversion by approximately 40%

  • Male gender, alcohol and smoking, young age and rural residence were

associated with longer time to culture conversion, thus are transmitting longer, more likely to have unfavourable outcomes

  • Anaemia among AFB smear positive women in rural areas may be

associated with longer time to culture conversion

slide-11
SLIDE 11

Thank You

  • CTRIUMPh

Study teams

  • Study

participant & their families